GlassScriptPhysician profile
Haifa Alrawi
NPI 1699410605
$1,293.46
in general payments reported to CMS, 2019-2025
8 companies · $1,071 in 2025
The $1,071 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $222 · 2025: $1,071.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,293.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,293.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $299.65 | 2024-2025 | Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $249.05 | 2024-2025 | Jardiance |
| Novo Nordisk INC | $236.30 | 2025 | Wegovy, Ozempic |
| Exact Sciences Corporation | $141.12 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $124.74 | 2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $124.73 | 2025 | Xifaxan |
| Axsome Therapeutics, INC. | $98.75 | 2025 | Auvelity |
| Amgen INC. | $19.12 | 2024 | Otezla, Repatha |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Haifa Alrawi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.